Generally, our study proved that ImI-modified micelles had targeting ability to NSCLC in addition to breast cancer and it may provide a promising strategy to deliver drugs to NSCLC overexpressing α7-nAChR. This evidence concerns the gene CHRNA7 and non-small cell lung carcinoma.